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Abstract
A healthy vascular endothelium is coated by the endo-
thelial glycocalyx. Its main constituents are transmem-
brane syndecans and bound heparan sulphates. This
structure maintains the physiological endothelial perme-
ability barrier and prevents leukocyte and platelet adhe-
sion, thereby mitigating inflammation and tissue oedema.
Heparinase, a bacterial analogue to heparanase, is
known to attack the glycocalyx. However, the exact
extent and specificity of degradation is unresolved. We
show by electron microscopy, immunohistological stain-
ing and quantitative measurements of the constituent
parts, that heparinase selectively sheds heparan sulphate
from the glycocalyx, but not the syndecans.
Keywords: coronary system; endothelium; heart;
permeability barrier; syndecans.
A healthy vascular endothelium is coated by a variety of
transmembrane syndecans and membrane-bound gly-
picans, both containing heparan sulphate and chondro-
itin sulphate side chains, which, together with many
shorter membrane proteins, constitute the endothelial
glycocalyx (Pries et al., 2000; Rehm et al., 2004). The
most common glycosaminoglycan on the endothelial gly-
cocalyx is heparan sulphate (Bernfield et al., 1999; Pries
et al., 2000). Principal proteins that carry bound heparan
sulphate – the proteoglycans – are the transmembrane
syndecans. The most prevalent proteoglycan on the
vascular endothelium is syndecan-1 (Pries et al., 2000;
Alexopoulou et al., 2007). It is well recognised that enzy-
matic digestion with heparinase, a bacterial analogue to
heparanase, or with pronase, as well as exposure to
tumour necrosis factor-a (TNF-a), ischaemia or major
surgery can reduce the thickness of the endothelial
glycocalyx, deteriorating the vascular barrier (Henry and
Duling, 2000; Rehm et al., 2004).
In vivo, the glycocalyx binds plasma proteins, forming
the endothelial surface layer. This has been demonstrat-
ed as an exclusion zone, e.g., for circulating erythrocytes
(Pries et al., 2000; Pries and Kuebler, 2006). To date,
there has been no direct visualisation of the glycocalyx
in humans, mainly due to the fact that the structure is
very fragile and easily deteriorates (Pries et al., 2000).
Therefore, one possibility to investigate the state of the
glycocalyx is to measure retention or shedding of its
constituent parts, e.g., heparan sulphate, syndecan-1 or
hyaluronan (Rehm et al., 2001; Nieuwdorp et al., 2006).
We chose to investigate the effect of heparinase on
heparan sulphate and syndecan-1, as hyaluronan has
been reported only to be part of the endothelial surface
layer and not of the glycocalyx itself (Pries and Kuebler,
2006). Here we show, for the first time, visually and quan-
titatively, that heparinase selectively sheds heparan sul-
phate, but not syndecan-1 off the glycocalyx in an intact
vascular bed, namely the coronary system of the isolated
perfused guinea-pig heart. This may help to elucidate the
role of heparan sulphate in the regulation of vascular
properties (Rehm et al., 2004; Jacob et al., 2006, 2007).
Guinea-pig hearts were isolated and perfused at con-
stant coronary flow rate in a modified Langendorff mode,
as described previously (Rehm et al., 2004; Jacob et al.,
2006). Coronary venous effluent was collected from the
cannulated pulmonary artery after draining from the cor-
onary sinus into the right atrium and ventricle. After an
equilibration time of 15 min to establish steady-state
conditions, enzymatic degradation of the glycocalyx was
performed by infusing heparinase, 10 U of enzyme (hepa-
rinase type I; Sigma-Aldrich, Seelze, Germany) being
applied into the intact coronary system in the course
of 10 min. Concentrations of heparan sulphate and
syndecan-1 in the coronary effluent were determined
using an ELISA (Seikagaku Corporation, Tokyo, Japan)
or an enzyme-linked immunosorbent assay (Diaclone
Research, Besancon, France), respectively. To visualise
the glycocalyx with the electron microscope, hearts were
perfusion-fixed at the end of the protocol via the aorta
and coronary arteries with a solution containing 2%
glutaraldehyde, 2% sucrose, 0.1 M sodium cacodylate
phosphate, and 2% lanthanum nitrate (Vogel et al., 2000).
Lanthanum is a trivalent cation and binds to negatively
charged glycoprotein moieties of the glycocalyx, stabilis-
ing the structure during fixation. For light microscopy and
immunohistochemistry, the hearts were perfusion fixed
with 4% formaldehyde and then stored in 1% formal-
dehyde solution for 24 h. Paraffin sections (5 mm) were
stained with a monoclonal antibody against heparan sul-
phate (Seikagaku Corporation). Comparisons involving
two groups were made using the Wilcoxon test for
dependent data. A p-value of -0.05 was considered to
be statistically significant. The statistical software used
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Figure 1 Coronary washout of constituents of the endothelial
glycocalyx.
Release rates of syndecan-1 (top panel) and heparan sulphate
(bottom panel) in the coronary effluent before, during and after
treatment with heparinase (10 IU, 10 min). Values are mean"SD
of six hearts/group. *ps0.01 and p-0.05qheparinase vs. pre-
and post-heparinase, respectively.
to conduct the analyses was SigmaStat 3.5 (Systat Soft-
ware Inc., San Jose, CA, USA).
Small amounts of heparan sulphate and syndecan-1
were detectable in the coronary effluent under basal con-
ditions. Basal rates of release were 3.2"1.0 mg/min/g
and 0.14"0.02 mg/min/g, respectively (Figure 1). During
application of heparinase (10 min), the rate of syndecan-
1 release amounted to 0.12"0.24 mg/min/g in the last 5
min, while that of heparan sulphate rose to 30.3"4.1
mg/min/g. Thus, syndecan-1 concentrations showed no
difference (Ws-12, p)0.05), but highly significant
amounts of heparan sulphate were shed from the gly-
cocalyx (min 0–5: Ws-28, ps0.01). Shedding was main-
tained, albeit at a lower level, for approximately 15 min
during washout of the enzyme (Figure 1).
Electron microscopy showed a dramatic degradation
of the endothelial glycocalyx (from approximately 220 nm
to 20 nm) after application of heparinase (Figure 2). Light
microscopy and immunohistochemistry revealed heparan
sulphate-positive staining of endothelial cells of small
vessels and large arteries of the guinea-pig heart (Figure
3A,C). Also, the walls of the vasculature contained hepa-
ran sulphate. After application of heparinase, the staining
of the endothelial cell lining was markedly reduced in all
types of vessels (Figure 3B,D). Thus, shedding of hepa-
ran sulphate off the endothelial surface is induced by
heparinase. Enzymograms (PAGE, gelatine) showed that
heparinase has no collagenase activity vs. control,
excluding enzyme activity, e.g., against the basement
membrane. This speaks against any substantial non-
specific protease activity of the applied enzyme.
Until today, the exact structure and function of the vas-
cular endothelial glycocalyx is still uncertain. For many
years, it was known as a layer with a thickness of only a
few tens of nanometres (Luft, 1966). Over the past years,
several animal studies have suggested the glycocalyx to
be much thicker and to be involved in a substantial num-
ber of physiological and pathophysiological processes.
Especially, it plays a major role in the vascular barrier
function (Rehm et al., 2004; Jacob et al., 2006, 2007).
Together with bound plasma proteins and solubilised
glycosaminoglycans, the glycocalyx forms the endothe-
lial surface layer with a thickness of approximately 1 mm
(Pries et al., 2000). The glycocalyx is also composed of
membrane-bound molecular components, such as cell
adhesion molecules, e.g., integrins and selectins (Pries
et al., 2000), and binds and intercalates inflammatory
cytokines and components of the coagulation system,
e.g., tissue factor and fibrinogen (Shih and Hajjar, 1993).
As the endothelial surface layer constitutes the first con-
tact surface between blood and tissue, it is essentially
involved in processes such as inflammation, coagulation
and firm adhesion of leukocytes and platelets to the vas-
cular wall. The importance of the endothelial glycocalyx
in situ has been clearly shown after its perturbation in
various animal studies (Henry and Duling, 2000; Rehm et
al., 2004; Bruegger et al., 2005; Jacob et al., 2006).
There are no data available as to the possible physi-
ological regulation of the glycocalyx or the rate of re-
covery after damage. However, endothelial caveolae are
densely packed with glycocalyx, which might represent
a reservoir for deployment on the endothelial surface
(Jacob et al., 2007). Moreover, we believe that the gly-
cocalyx will be more susceptible to deterioration if the
endothelial surface layer is altered. As this mainly con-
sists of intercalated plasma proteins and hyaluronan and
is not anchored in the endothelial membrane, it may be
able to re-organise itself much more easily than the
glycocalyx.
Diminution of the glycocalyx leads to activation of
coagulation, leukocyte and platelet adhesion and
increases capillary permeability, leading to tissue oedema
(van den Berg et al., 2003). Furthermore, ischaemia/
reperfusion impairs shear-stress mediated, endothelium
(nitric oxide)-dependent coronary vasodilatation, contri-
buting to low reflow, and leads to damage of the coro-
nary endothelium (Bouchard and Lamontagne, 1999). In
isolated heart preparations, as used here, ischaemia/
reperfusion was found to increase shedding of heparan
sulphate approximately 30-fold (Chappell et al., 2006). In
contrast, washout of hyaluronan was increased only 3-
fold above basal, even under such extreme conditions
(unpublished results). Surgical stress is believed to
deteriorate the endothelial glycocalyx to some degree,
depending on the severity of the trauma. Indeed, mani-
festation of endothelial injury consists of a disruption of
the glycocalyx. As illustrated in the present work, the ten-
dency for syndecan-1 release in the venous effluent of
isolated hearts to decrease with time might result from a
recovery of the coronary endothelium after the surgical
preparation.
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Figure 2 Electron micrographs of the endothelial glycocalyx in isolated perfused hearts (guinea-pig).
An intact glycocalyx is shown in an untreated control heart: panel (A) (overview) and panel (C) (close-up). After application of hepar-
inase, the glycocalyx was deteriorated: panel (B) (overview) and panel (D) (close-up).
Figure 3 Immunostaining of coronary microvessels (panels A
and B) and coronary artery (panels C and D) with a monoclonal
antibody against heparan sulphate.
Guinea-pig hearts were perfused without heparinase (panels A
and C) and with heparinase (panels B and D). The original mag-
nification was 60= in all cases. E: endothelium; VL: vascular
lumen.
Heparinase is a bacterial analogue to heparanase, a
mammalian endoglycosidase participating in degradation
and remodelling of the extracellular matrix and facilitating
cell invasion associated with inflammation or cancer
metastasis (Myler and West, 2002). In how far shedding
of merely the charged heparan sulphate side-groups
contributes to these pathophysiological phenomena in
vivo remains to be determined.
In conclusion, heparinase specifically induces shed-
ding of heparan sulphate from the glycocalyx, thereby
deteriorating the vascular barrier, while syndecan-1
remains on the endothelial surface. This scaffolding
seems to ‘collapse’, forming a thin layer of only one-tenth
of the original thickness at the endothelial surface. As
shown previously, such a rudimentary glycocalyx loses
much of its ability to mediate shear stress to the endo-
thelial cells and to act as a second barrier against vas-
cular leakage.
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